The Bio Report

36

The Bio Report podcast, hosted by award-winning journalist Daniel Levine, focuses on the intersection of biotechnology with business, science, and policy.

Recent Episodes
  • Revolutionizing the Production of Biologics with Algae
    Jun 4, 2025 – 37:52
  • Making Medicines for a World of People with Cancer
    May 28, 2025 – 42:59
  • Harnessing Myeloid Cells to Attack Cancer
    May 21, 2025 – 37:00
  • Drawing Lessons from the COVID Pandemic
    May 14, 2025 – 32:05
  • A Bet that Myostatins Can Muscle Out Obesity
    May 7, 2025 – 29:51
  • Making Whole-Eye Transplantation a Reality
    Apr 30, 2025 – 25:04
  • Synbio Companies Come to Grips with the One “Omic” that Matters
    Apr 23, 2025 – 34:38
  • Searching for Safer Pain Medications
    Apr 16, 2025 – 39:19
  • Bridging the Translational Divide in Healthcare AI
    Apr 9, 2025 – 27:45
  • Seeking Long-Term Pain Relief from a Drug-Free Injection
    Apr 2, 2025 – 29:10
  • Engaging Hard-to-Target Receptors with Antibodies that Activate
    Mar 26, 2025 – 39:43
  • An Insider’s View of the Patent Fights that Shaped the Biotech Industry
    Mar 19, 2025 – 01:11:18
  • Restoring Balance to the Immune System in Allergic Diseases
    Mar 12, 2025 – 28:36
  • Turning Natural Killers into Off-the-Shelf Therapies for Autoimmune Disease
    Mar 5, 2025 – 32:09
  • Combining an Antibody and siRNA to Treat Hepatitis B
    Feb 26, 2025 – 29:28
  • Looking at the Promise of GLP-1 Agonists Beyond Obesity
    Feb 19, 2025 – 22:20
  • An Off-the-Shelf Cancer Vaccine Faces a Final Clinical Hurdle in NSCLC
    Feb 12, 2025 – 31:20
  • A Nose for Attacking Brain Cancer
    Feb 5, 2025 – 08:54
  • An Unnatural Approach to Undruggable Targets
    Jan 29, 2025 – 24:52
  • Expanding the Drug Developer’s Chemical Universe
    Jan 22, 2025 – 33:52
  • Take 100 Megabytes a Day and Call Me in the Morning
    Jan 15, 2025 – 29:20
  • Extracting the Benefits of Psychedelics
    Jan 8, 2025 – 34:25
  • A Magellan that Circumnavigates Active Binding Sites
    Jan 1, 2025 – 37:40
  • A Very Meh-Ry Biotech Year and What’s Ahead in 2025
    Dec 25, 2024 – 40:28
  • Using Light to Biomanufacture a Steak
    Dec 18, 2024 – 33:43
  • Sit, Stay, and Heal: Bringing Precision Medicine to Dogs, then Humans
    Dec 11, 2024 – 34:46
  • Targeting the Undruggable Proteome
    Dec 4, 2024 – 32:31
  • Preventing a Deadly Disease by Detecting It Before It Becomes Cancer
    Nov 26, 2024 – 36:44
  • Getting Tumors to Say “Eat Me”
    Nov 20, 2024 – 25:08
  • Targeting the Dark Matter of the Genome to Treat Diseases
    Nov 13, 2024 – 32:33
  • Using AI to Discover Small Molecule Alternatives to Biologics
    Nov 6, 2024 – 31:33
  • A BET on a Novel Approach to Treat Autoimmune Conditions
    Oct 30, 2024 – 24:40
  • Cell Therapies that Can Do a Solid for People with Cancer
    Oct 23, 2024 – 51:49
  • Going to Extremes to Discover New Drugs
    Oct 16, 2024 – 31:38
  • Targeting Senescent Cells to Treat Aging-Related Diseases
    Oct 9, 2024 – 31:44
  • Bringing Cellular Diversity into Sharper Focus
    Oct 2, 2024 – 30:35
  • Developing Cancer Therapies for When Damage Control Goes Awry
    Sep 25, 2024 – 18:09
  • Delivering the Goods
    Sep 25, 2024 – 36:06
  • Swimming in the New Oil
    Sep 11, 2024 – 22:26
  • Does This Drug Represent “A Paradigm Shift for Small Molecule Drug Development?”
    Sep 4, 2024 – 28:01
  • Exploring the Promise and Peril of CRISPR
    Aug 28, 2024 – 57:36
  • Transforming Protein Engineering with Generative AI
    Aug 21, 2024 – 35:47
  • Delivering Peptide Therapies Orally
    Aug 14, 2024 – 34:06
  • Creating A Drug Delivery ARMMs Race
    Aug 7, 2024 – 24:42
  • A Seek and Destroy Approach to Disease-Causing Proteins
    Jul 31, 2024 – 37:10
  • Teaching Tolerance to Address Autoimmune Diseases
    Jul 24, 2024 – 36:25
  • A Bet That the Next Blockbuster May Already Be Inside You
    Jul 17, 2024 – 22:34
  • A Big Mac Attack to Fight Cancer
    Jul 10, 2024 – 36:37
  • Getting Animated about Bioliteracy
    Jul 3, 2024 – 24:29
  • Reshaping Clinical Trial Designs with Real-World Data
    Jun 26, 2024 – 28:53
Recent Reviews
  • Snsn snsnsn
    Poor interviewing skills
    It is clear the host is just reading from a script. It’s very distracting the way he pauses in weird places in sentences. And then he essentially ignores what the guest is saying. No follow up questions, no listening, no semblance of conversation, just on to the next canned question. I suggest the host listens to his own interview with Kolluri—he rudely interrupts him several times, and for what reason? Simply to ask his next canned question! It’s so strange. It doesn’t sound like a big deal, but all of this is so distracting that it makes it difficult to focus on the content.
  • DanP9191
    Too loud
    The content is interesting and it’s one of the podcasts I listen to most, but the advertisement and especially the jazz transition music is SO LOUD. When I’m driving and my hands are occupied, I actively cringe at the expectation of having my eardrums blasted when an episode begins or ends. When I’m not driving I try to skip ahead to the ~2 minute mark, because missing a bit of starting context from the actual show is worth preserving my hearing. Please make the audio levels consistent.
  • NotRecommended1
    Not for physicians
    I’m a physician doing translational research in gene therapy. At least for the medical part the interviews discuss inaccurate information. For example there’s a talk where the interviewee says that in medicine therapy for most or all diseases are only symptom based “...such as diabetes and cancer...” which is absolutely wrong as especially in these diseases therapy starts as early as possible specifically to prevent symptoms. In addition there are some interviews where it seems that the members of the discussion haven’t discussed before hand what points will be touched and sometimes the interviewee “corrects the interviewer” which makes listening confusing. I’m unsubscribing and will search for other translational gene therapy research podcasts.
  • bman90254
    Paid for advertising?
    I can see the relevance for investors to hear these advertisements, however, as a scientist I fail to see the value.
  • DGrande
    Sound quality lacking, but great content
    Can’t understand why this isn’t more popular...it’s incredibly relevant, instructive, and brings in great guests. These are the things I need to know for my team and company. 5 stars.
  • Inrater
    Good content
    I am a longtime investor in Biotech and find the topics and interviews extremely interesting. The sound is not that good but it really doesn’t matter when the content is interesting. I would shorten the intro jingle by 50%. Keep up the good work.
  • Crob9120
    Audio quality is horrible
    Sounds like he just records the speaker phone audio...
  • PhelineCat
    Crushingly disappointing
    I particularly wanted to hear the episode for August 17, 2017- since Reagan there's been excessive focus on shareholders instead of long term company health and employee retention and morale across all industries- but the sound quality was terrible. I tried a few other episodes and I knew I wasn't going to get anything out of this pod because of the poor recording and editing. My suggestions- 1. Spend time learning to do a better job with what you have. There are mentors out there who understand you need knowledge first. 2. Add to your equipment slowly in an as needed basis. Buying the best won't help if you still don't know how to use it. That's the technical stuff but I can't address content. What I hope this podcast does is knock Reagan off his artificial pedestal of broken economic policies- people began suffering in uncounted ways and the stock market solidified that.
Disclaimer: The podcast and artwork on this page are property of the podcast owner, and not endorsed by UP.audio.